Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:53:30 EDT Wed 13 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:UTHR - UNITED THERAPEUTICS CORP - https://www.unither.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
UTHR - Q1.8575.30·578.850.3576.7408-4.9992-0.95.53,201197580.05  581.17  576.7408609.35  272.17509:32:51May 1215 min RT 2¢

Recent Trades - Last 10 of 197
Time ETExPriceChangeVolume
09:32:51Q578.80-2.941
09:32:48Q574.84-6.901
09:32:45Q576.82-4.922
09:32:43Q577.8766-3.86341
09:32:42Q576.82-4.921
09:32:38Q576.82-4.921
09:32:28Q576.82-4.921
09:32:24Q576.82-4.921
09:32:23Q576.82-4.921
09:32:12Q577.0571-4.68295

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-12 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
2026-05-11 06:30U:UTHRNews ReleaseUnited Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
2026-05-06 06:30U:UTHRNews ReleaseUnited Therapeutics Corporation Reports First Quarter 2026 Financial Results
2026-05-06 06:30U:UTHRNews ReleaseMannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
2026-04-29 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
2026-04-22 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
2026-04-20 06:30U:UTHRNews ReleaseUnited Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
2026-04-08 07:00U:UTHRNews ReleaseUnited Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP(TM) for Treatment of Acute Liver Failure
2026-03-30 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso(TM) Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
2026-03-09 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
2026-03-03 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
2026-03-02 06:30U:UTHRNews ReleaseUnited Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
2026-02-25 06:30U:UTHRNews ReleaseUnited Therapeutics Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-23 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Present at the TD Cowen 46th Annual Health Care Conference
2026-02-11 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
2026-01-26 07:00U:UTHRNews ReleaseUnited Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP(TM) in Patients with Acute Liver Failure
2026-01-22 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
2026-01-05 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-11-04 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation to Present at Upcoming Investor Conferences
2025-11-03 07:00U:UTHRNews ReleaseUnited Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease